InvestorsHub Logo
Followers 23
Posts 2523
Boards Moderated 0
Alias Born 10/26/2003

Re: DewDiligence post# 1560

Tuesday, 11/21/2017 8:15:27 PM

Tuesday, November 21, 2017 8:15:27 PM

Post# of 2929

I thought the magnitude of today's selloff was unwarranted given my view of ENTA’s prospects for the next couple of years and beyond.


What are your thoughts on the value of ENTA's Mavyret/HepC drugs? ENTA currently has approx $14/share in net cash leaving $30 left for everything else (HepC, Nash, etc.). Mavyret/HepC drugs are likely worth at least $30/share ($600 million) and everything else is free.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News